Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Principal Investigator

Dr Jeremy Cobbold

Contact us

Email: ouh-tr.ctfresearch@nhs.net

IRAS number

1010199